Evaluating CAR T Cell Therapy Processing With The Sefia™ Expansion System Using Commercially Available Cell Culture Media

By Cindy Farino Reyes, Srinidhi Deshpande, Rubayat Jamal, Mack Ryan, Nick McKenzie, Craig Mizzoni, Yanling Liu, Anna Maystrenko, Dana Arab, Darryl Knight, Mojtaba Parvizi, and Federico Franchi

Advances in autologous CAR T cell therapies have transformed cell therapy development, supported by refined engineering approaches and innovations in media and cytokine design. The shift toward serum-free media has improved consistency, reproducibility, and process control—key factors for scalable manufacturing. As platforms evolve, flexibility becomes essential. Media-agnostic T cell manufacturing systems enable seamless adaptation across workflows, reducing the need for re-optimization when conditions change. This adaptability helps accelerate development timelines while maintaining product quality. For teams navigating increasingly complex production environments, building workflows that perform reliably across media types is becoming a strategic advantage.

Explore how embracing media-agnostic approaches can strengthen process resilience and support the next generation of CAR T innovations.